TY - JOUR
T1 - Effect of post–cesarean delivery oral cephalexin and metronidazole on surgical site infection among obese women
T2 - A randomized clinical trial
AU - Valent, Amy M.
AU - Dearmond, Chris
AU - Houston, Judy M.
AU - Reddy, Srinidhi
AU - Masters, Heather R.
AU - Gold, Alison
AU - Boldt, Michael
AU - Defranco, Emily
AU - Evans, Arthur T.
AU - Warshak, Carri R.
N1 - Funding Information:
Author Contributions: Dr Warshak had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Houston, DeFranco, Evans, Warshak. Acquisition, analysis, or interpretation of data: Valent, DeArmond, Reddy, Masters, Gold, Boldt, DeFranco, Evans, Warshak. Drafting of the manuscript: Valent, DeArmond, Masters, DeFranco, Warshak. Critical revision of the manuscript for important intellectual content: Valent, Houston, Reddy, Gold, Boldt, DeFranco, Evans, Warshak. Statistical analysis: DeFranco. Obtained funding: Warshak. Administrative, technical, or material support: Valent, Houston, Masters, Gold, DeFranco, Warshak. Supervision: Valent, DeFranco, Evans, Warshak. Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. Funding/Support: This trial was sponsored by the University of Cincinnati Department of Obstetrics and Gynecology, Cincinnati, Ohio. Role of the Funder/Sponsor: The University of Cincinnati Department of Obstetrics and Gynecology was not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Publisher Copyright:
© 2017 American Medical Association. All rights reserved.
PY - 2017/9/19
Y1 - 2017/9/19
N2 - IMPORTANCE: The rate of obesity among US women has been increasing, and obesity is associated with increased risk of surgical site infection (SSI) following cesarean delivery. The optimal perioperative antibiotic prophylactic regimen in this high-risk population undergoing cesarean delivery is unknown. OBJECTIVE: To determine rates of SSI among obese women who receive prophylactic oral cephalexin and metronidazole vs placebo for 48 hours following cesarean delivery. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind clinical trial comparing oral cephalexin and metronidazole vs placebo for 48 hours following cesarean delivery for the prevention of SSI in obese women (prepregnancy BMI ≥30) who had received standard intravenous preoperative cephalosporin prophylaxis. Randomization was stratified by intact vs rupture of membranes prior to delivery. The study was conducted at the University of Cincinnati Medical Center, Cincinnati, Ohio, an academic and urban setting, between October 2010 and December 2015, with final follow-up through February 2016. INTERVENTIONS: Participants were randomly assigned to receive oral cephalexin, 500 mg, and metronidazole, 500 mg (n = 202 participants), vs identical-appearing placebo (n = 201 participants) every 8 hours for a total of 48 hours following cesarean delivery. MAIN OUTCOMES AND MEASURES: The primary outcome was SSI, defined as any superficial incisional, deep incisional, or organ/space infections within 30 days after cesarean delivery. RESULTS: Among 403 randomized participants who were included (mean age, 28 [SD, 6] years; mean BMI, 39.7 [SD, 7.8]), 382 (94.6%) completed the trial. The overall rate of SSI was 10.9% (95% CI, 7.9%-14.0%). Surgical site infection was diagnosed in 13 women (6.4%) in the cephalexin-metronidazole group vs 31 women (15.4%) in the placebo group (difference, 9.0% [95% CI, 2.9%-15.0%]; relative risk, 0.41 [95% CI, 0.22-0.77]; P = .01). There were no serious adverse events, including allergic reaction, reported in either the antibiotic group or the placebo group. CONCLUSIONS AND RELEVANCE: Among obese women undergoing cesarean delivery who received the standard preoperative cephalosporin prophylaxis, a postoperative 48-hour course of oral cephalexin and metronidazole, compared with placebo, reduced the rate of SSI within 30 days after delivery. For prevention of SSI among obese women after cesarean delivery, prophylactic oral cephalexin and metronidazole may be warranted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01194115.
AB - IMPORTANCE: The rate of obesity among US women has been increasing, and obesity is associated with increased risk of surgical site infection (SSI) following cesarean delivery. The optimal perioperative antibiotic prophylactic regimen in this high-risk population undergoing cesarean delivery is unknown. OBJECTIVE: To determine rates of SSI among obese women who receive prophylactic oral cephalexin and metronidazole vs placebo for 48 hours following cesarean delivery. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind clinical trial comparing oral cephalexin and metronidazole vs placebo for 48 hours following cesarean delivery for the prevention of SSI in obese women (prepregnancy BMI ≥30) who had received standard intravenous preoperative cephalosporin prophylaxis. Randomization was stratified by intact vs rupture of membranes prior to delivery. The study was conducted at the University of Cincinnati Medical Center, Cincinnati, Ohio, an academic and urban setting, between October 2010 and December 2015, with final follow-up through February 2016. INTERVENTIONS: Participants were randomly assigned to receive oral cephalexin, 500 mg, and metronidazole, 500 mg (n = 202 participants), vs identical-appearing placebo (n = 201 participants) every 8 hours for a total of 48 hours following cesarean delivery. MAIN OUTCOMES AND MEASURES: The primary outcome was SSI, defined as any superficial incisional, deep incisional, or organ/space infections within 30 days after cesarean delivery. RESULTS: Among 403 randomized participants who were included (mean age, 28 [SD, 6] years; mean BMI, 39.7 [SD, 7.8]), 382 (94.6%) completed the trial. The overall rate of SSI was 10.9% (95% CI, 7.9%-14.0%). Surgical site infection was diagnosed in 13 women (6.4%) in the cephalexin-metronidazole group vs 31 women (15.4%) in the placebo group (difference, 9.0% [95% CI, 2.9%-15.0%]; relative risk, 0.41 [95% CI, 0.22-0.77]; P = .01). There were no serious adverse events, including allergic reaction, reported in either the antibiotic group or the placebo group. CONCLUSIONS AND RELEVANCE: Among obese women undergoing cesarean delivery who received the standard preoperative cephalosporin prophylaxis, a postoperative 48-hour course of oral cephalexin and metronidazole, compared with placebo, reduced the rate of SSI within 30 days after delivery. For prevention of SSI among obese women after cesarean delivery, prophylactic oral cephalexin and metronidazole may be warranted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01194115.
UR - http://www.scopus.com/inward/record.url?scp=85029622393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029622393&partnerID=8YFLogxK
U2 - 10.1001/jama.2017.10567
DO - 10.1001/jama.2017.10567
M3 - Article
C2 - 28975304
AN - SCOPUS:85029622393
SN - 0098-7484
VL - 318
SP - 1026
EP - 1034
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 11
ER -